降压药依普利酮需要吃多久见效

The new generation of selective aldosterone antagonist was developed by Pfizer/Pharmacia with the trade name Inspra. It was first launched in the United States in 2002 and applied for patent protection in China in 2006.

Eplerenone is used for essential hypertension and heart failure after myocardial infarction. For severe hypertension that cannot be controlled by a combination of multiple antihypertensive drugs, the addition of eplerenone can significantly reduce blood pressure, especially the decrease in systolic blood pressure is more significant. Combined treatment with angiotensin-converting enzyme inhibitors (ACEI) and beta-blockers can improve patients' quality of life and reduce mortality in severe heart failure and myocardial infarction.

In clinical studies, it has been found that the drug eplerenone, which treats high blood pressure, is also effective in treating chronic kidney disease caused by excessive salt intake. In the future, this antihypertensive drug is expected to become a new option when treating patients with chronic kidney disease accompanied by hypertension.

Eplerenone is a new type of selective aldosterone receptor blocker that can effectively control hypertension, reduce damage to target organs such as the heart, brain and kidneys, and improve microalbuminuria in patients with type 2 diabetes. Eplerenone is a new type of selective aldosterone receptor antagonist that was approved for clinical use by the State Food and Drug Administration in 2002. It has stronger aldosterone antagonism than spironolactone and has extremely low affinity for androgen and progesterone receptors. It has few adverse reactions. It has definite efficacy in the treatment of hypertension, heart failure and myocardial infarction. It has fewer adverse reactions and good tolerance. It is a good alternative drug to spironolactone.

In addition, precautions for using eplerenone include:

(1) Eplerenone cannot be combined with potassium supplements, potassium-containing salts or contraindicated drugs (potassium-sparing diuretics, strong inhibitors of CYP450 liver enzymes).

(2) Non-steroidal anti-inflammatory drugs and lithium can affect the blood concentration of eplerenone and affect the efficacy.

(3) Patients with high serum potassium, type 2 diabetes patients with microalbuminuria, patients with high serum creatinine levels, and patients with muscle intoxication clearance <50 mL/min should not take this product.

(4) Pregnant women, children, and those with hepatic insufficiency, chronic cardiac insufficiency, and renal insufficiency should use with caution.

Recommended related hot articles: /newsDetail/79995.html